āĻšā§āĻŽBT3 âĸ FRA
add
Lineage Cell Therapeutics Inc
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Ļ.ā§Šā§âŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Ļ.ā§Šā§ŽâŦ - ā§Ļ.ā§Ēā§ĻâŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§Ļ.ā§Šā§ŠâŦ - ā§§.⧍ā§ĒâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§§ā§Ļ.ā§Šā§¯Â āĻā§ USD
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
ā§Ŧ.ā§Ļā§Ļ
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻŦāĻžāĻāĻžāϰ āϏāĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
(USD) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§¨ā§Ž.ā§Ŧā§ŽÂ āϞāĻž | ā§Šā§.ā§Šā§Ŧ% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§Ēā§Ē.ā§Ļā§§Â āϞāĻž | ā§Ēā§Žā§Ļ.ā§Ŧā§§% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§Šā§¨.ā§ā§ŠÂ āϞāĻž | ā§Šā§§.ā§Ēā§Ŧ% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | -ā§§ā§§ā§Ē.⧧⧍ | ā§Ģā§Ļ.ā§§ā§Ļ% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | -ā§Ļ.ā§Ļā§§ | ā§Ŧā§Š.⧍ā§Ē% |
EBITDA | -ā§Ē⧝.ā§Ģā§¯Â āϞāĻž | -ā§Žā§Ŧ.ā§Ŧā§Ē% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | â | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(USD) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ā§Ē.ā§ā§ŽÂ āĻā§ | ā§Šā§Ē.ā§Ŧ⧝% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§§ā§§.ā§Šā§¨Â āĻā§ | ⧧⧍.ā§Ļā§Ž% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Š.ā§Ŧā§¨Â āĻā§ | -ā§.ā§§ā§Ģ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§.ā§ā§Ļ āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ⧍⧍.ā§Žā§Ē āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§§.ā§Ļā§Ē | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -⧧⧍.ā§§ā§Ž% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | -ā§§ā§.ā§Šā§% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
(USD) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§Šā§¨.ā§ā§ŠÂ āϞāĻž | ā§Šā§§.ā§Ēā§Ŧ% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | -ā§Ŧā§Š.ā§Ēā§Ŧ āϞāĻž | -ā§Ģ.ā§Ēā§Š% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ⧍ā§Ŧ.ā§Šā§Ģ āϞāĻž | -ā§ā§¨.⧝ā§Ģ% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ⧍.ā§§ā§Â āĻā§ | ā§§ā§Ŧā§,ā§¨ā§Žā§Ē.ā§Ŧ⧍% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | ā§§.ā§Žā§Ļ āĻā§ | ā§Šā§Ģ⧍.ā§§ā§Ļ% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -ā§Šā§Ē.⧝ā§Â āϞāĻž | -ā§Ģ⧝ā§Ē.ā§Ģ⧝% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineageâs programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
⧧⧝⧝ā§Ļ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§ā§Ē